Practical, engaging health care regulatory and transactional counsel

Katie Lavigne assists clients with a diverse range of regulatory issues and transactional matters. She offers practical legal counsel to clients on a wide range of pharmacy regulatory issues such as controlled substances and state licensure compliance. Katie's work also involves advising pharmacy benefit manager, insurance carrier and third-party administrator clients to understand an ever-changing regulatory landscape with multifaceted implications across business segments. She has experience with credit card compliance, program audits, federal and state health care laws and regulations, and Medicare Part D pharmacy benefits.

Prior to joining Quarles, Katie worked for a PBM and a global health care services company. Her previous business experience and acumen allows her to bring a unique perspective to her legal work when advising clients.

Bar Admissions

• Minnesota

Education

• Mitchell Hamline School of Law (J.D., summa cum laude, 2020)

• University of St. Thomas (B.A., magna cum laude, 2010)

• "PBMs, ERISA Preemption, Rutledge v. PCMA, and Resulting State Laws: The Continuing Story"
• "Pharmacy Law Update"
• FDA REMS Protocol Modification Provides a Pathway for Pharmacies to Dispense Mifepristone
• Georgia Board of Pharmacy Continues to Review Licensure Requirements for Pharmacists
• Illinois Proposes Licensure for Pharmacists-in-Charge of Nonresident Pharmacies
• Jaya White and Katie Lavigne Author Pharmacy Times Article About Questions Surrounding Mifepristone Distribution by Mail Order Pharmacies
• Jaya White and Katie Lavigne Outline Mifepristone Considerations for Pharmacies in Article for Healthcare Business Today
• Kentucky Withdraws Controversial Non-Resident Pharmacist License Regulation
• New York State Department of Financial Services Reporting Requirements for Pharmacy Benefit Managers
• Oklahoma Patient's Right to Pharmacy Choice Act Preempted by ERISA
• Revised Amendments to Texas Central Fill Rule Address Concerns for Misinterpretation
• The Lower Costs More Transparency Act of 2023
• “Pharmacy Law Update”

Seminar

• 2023 Pharmacy Law Symposium
• 2024 Pharmacy Law Symposium